Form 4: Biohaven Director Kishan Mehta Receives Stock Options

Director Kishan Mehta was granted 68,693 stock options in Biohaven Ltd. as part of standard equity compensation.

Summary

• Director Kishan Mehta received a grant of 68,693 stock options on April 28, 2026.
• The options have an exercise price of $9.61 per share.
• The options are set to expire on April 28, 2036.
• Vesting is scheduled for the earlier of April 28, 2027, or the date of the 2027 Annual Meeting of Shareholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• Results in potential future dilution of existing shareholders upon exercise of the options.

Risks

• Market volatility could impact the value of the options relative to the exercise price.

Future Outlook

The options vest in one year, contingent upon the director's continued service to the company.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to ensure leadership retention and alignment with corporate performance goals.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical director compensation packages for mid-cap biotechnology firms.
• The use of a one-year cliff vesting period is a common industry standard for non-employee director equity awards.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Director to remain in service through April 2027 to satisfy vesting requirements.

Key Dates

Keywords

Biohaven, BHVN, Form 4, Insider Trading, Stock Options, Director Compensation